Sign up to save your podcasts
Or
Share ASCO 2026 Plenary: RASolute-302
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ASCO 2026 Plenary: RASolute-302
This week’s episode will be focusing on the 2026 ASCO Plenary that received a standing ovation, the RASolute 302 trial.
The RASolute 302 trial is a landmark phase 3 study demonstrating that daraxonrasib doubled overall survival compared to chemotherapy in previously treated (2L) metastatic pancreatic ductal adenocarcinoma (mPDAC).
View all episodes
By Sam and Karine
4.8
193193 ratings
This week’s episode will be focusing on the 2026 ASCO Plenary that received a standing ovation, the RASolute 302 trial.
The RASolute 302 trial is a landmark phase 3 study demonstrating that daraxonrasib doubled overall survival compared to chemotherapy in previously treated (2L) metastatic pancreatic ductal adenocarcinoma (mPDAC).
More shows like Two Onc Docs
View all
NEJM This Week
317 Listeners
JAMA Clinical Reviews
504 Listeners
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Research To Practice | Oncology Videos
121 Listeners
ASCO Daily News
58 Listeners
The Curbsiders Internal Medicine Podcast
3,364 Listeners
Core IM | Internal Medicine Podcast
1,152 Listeners
OncoPharm
187 Listeners
ASCO Guidelines
46 Listeners
The Clinical Problem Solvers
516 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
376 Listeners
Blood Podcast
52 Listeners
Oncology Today with Dr Neil Love
59 Listeners
Blood Cancer Talks
51 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
47 Listeners